Fuji Pharma Co., Ltd. (JP:4554)
:4554
4554 Stock Chart & Stats
¥1888.00
-¥22.00(-1.41%)
At close: 4:00 PM EST
¥1888.00
-¥22.00(-1.41%)
Day’s Range― - ―
52-Week Range¥1,232.00 - ¥2,559.00
Previous CloseN/A
Volume88.50K
Average Volume (3M)86.41K
Market Cap
¥63.93B
Enterprise Value¥87.77B
Total Cash (Recent Filing)¥7.25B
Total Debt (Recent Filing)¥30.94B
Price to Earnings (P/E)35.6
Beta0.86
Next Earnings
May 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.39%
Share Statistics
EPS (TTM)13.28
Shares Outstanding26,121,100
10 Day Avg. Volume111,080
30 Day Avg. Volume86,410
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)0.80
Price to Sales (P/S)0.73
P/FCF Ratio9.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)152.3
Revenue Forecast (FY)¥53.93B
Bulls Say, Bears Say
Bulls Say
Consistent Revenue GrowthSustained top-line expansion indicates durable demand for Fuji Pharma’s prescription portfolio and supports R&D and manufacturing scale. Over 2-6 months this underpins predictable sales cadence and reinvestment capacity, reducing reliance on one-off product wins.
Diversified Revenue Streams: Product Sales And CDMOA mixed model of branded/licensed product sales plus CDMO contract manufacturing provides recurring, contract-backed revenue alongside prescription-driven sales. This structural mix smooths volatility and leverages manufacturing assets for long-term margin and cash generation resilience.
Improving Free Cash Flow And Stable Equity RatioRising free cash flow and a stable equity ratio enhance financial flexibility to fund development, pay down debt, or invest in capacity. Over several months this strengthens balance sheet durability and reduces refinancing risk versus peers with weaker cash conversion.
Bears Say
Rising LeverageAn increasing debt-to-equity trajectory raises interest and refinancing risk and constrains strategic optionality. If leverage continues to climb, it can limit capital allocation to R&D or capacity expansion and make the firm more sensitive to rate moves over the medium term.
Margin Volatility And Recent Margin DeclineWider swings and recent deterioration in EBIT and net margins suggest pressure from pricing, product mix, or cost rises. Persistent margin instability undermines free cash flow predictability and heightens execution risk for sustaining investments and shareholder returns.
Weak Operating Cash Conversion And EPS DeclineDespite improved FCF, weaker cash conversion relative to reported earnings and a sharp EPS drop indicate potential quality-of-earnings or working capital pressure. This can limit reinvestment and increase reliance on external funding over several months.
Fuji Pharma Co., Ltd. News
4554 FAQ
What was Fuji Pharma Co., Ltd.’s price range in the past 12 months?
Fuji Pharma Co., Ltd. lowest stock price was ¥1232.00 and its highest was ¥2559.00 in the past 12 months.
What is Fuji Pharma Co., Ltd.’s market cap?
Fuji Pharma Co., Ltd.’s market cap is ¥63.93B.
When is Fuji Pharma Co., Ltd.’s upcoming earnings report date?
Fuji Pharma Co., Ltd.’s upcoming earnings report date is May 12, 2026 which is in 32 days.
How were Fuji Pharma Co., Ltd.’s earnings last quarter?
Fuji Pharma Co., Ltd. released its earnings results on Feb 05, 2026. The company reported ¥13.28 earnings per share for the quarter, beating the consensus estimate of N/A by ¥13.28.
Is Fuji Pharma Co., Ltd. overvalued?
According to Wall Street analysts Fuji Pharma Co., Ltd.’s price is currently Overvalued.
Does Fuji Pharma Co., Ltd. pay dividends?
Fuji Pharma Co., Ltd. pays a Semiannually dividend of ¥25.5 which represents an annual dividend yield of 2.39%. See more information on Fuji Pharma Co., Ltd. dividends here
What is Fuji Pharma Co., Ltd.’s EPS estimate?
Fuji Pharma Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fuji Pharma Co., Ltd. have?
Fuji Pharma Co., Ltd. has 26,121,100 shares outstanding.
What happened to Fuji Pharma Co., Ltd.’s price movement after its last earnings report?
Fuji Pharma Co., Ltd. reported an EPS of ¥13.28 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.157%.
Which hedge fund is a major shareholder of Fuji Pharma Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4554
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Fuji Pharma Co., Ltd.
Fuji Pharma Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceutical products in Japan and internationally. The company offers injection agents, internal drugs, drugs for external use, and diagnostic products. It also provides medical care for women; in vitro diagnostics, acute medical care products, and curative medicines; and information regarding pharmaceuticals and health. Fuji Pharma Co., Ltd. was incorporated in 1965 and is headquartered in Tokyo, Japan.
Technical Analysis
Mochida Pharmaceutical Co., Ltd.
―
Fuso Pharmaceutical Industries,Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
Daito Pharmaceutical Co., Ltd.
―
ASKA Pharmaceutical Holdings Co., Ltd.
―
Options Prices
Currently, No data available
---